T-CAF investment commitment · Biotech
Toyama Co-Accel Fund commits investment to LABTECHS
The fund will support commercialisation of rapid sterility testing and reagent technology.
Toyama Co-Accel Fund (T-CAF) has announced its first investment decision, backing LABTECHS. The amount and financing terms were not disclosed. Relic, the fund's general partner, will provide business-development support alongside capital.
LABTECHS, a University of Toyama spinout, sells the Decontami-Tech rapid sterility testing kit and is developing another reagent to shorten microbial testing. The partnership will support new applications, manufacturing capacity and distribution relationships with pharmaceutical, regenerative-medicine and testing-equipment businesses.
Use of funds
Rapid sterility testing commercialisation
Reagent manufacturing and distribution
Funding history
T-CAF investment commitment · This roundUndisclosed
Go-Tech research grant selectionUndisclosed